Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved? | Health
• Health Minister Mark Butler confirmed that key multiple sclerosis (MS) treatments, including Ocrevus, Kesimpta, and Lemtrada, will remain subsidized on the Pharmaceutical Benefits Scheme (PBS). • The decision follows a review by an expert advisory panel, ensuring that Australians living with MS maintain affordable access to these life-changing medications. • This move addresses growing concerns regarding the stability of taxpayer subsidies for high-cost specialty drugs and the potential for certain treatments to be removed from the scheme.
Read story


